The role of antibodies in inflammatory arthritis

Immunological Reviews

Volumn 233, Issue 1, 2010, Pages 112-125

  Duskin, Ann ^a   Eisenberg, Robert A ^b  

^a PENNSYLVANIA HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Arthritis; Autoantibody; Autoimmunity; Serology

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIPERINUCLEAR FACTOR; BACTERIUM ANTIBODY; COLLAGEN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLUCOSE 6 PHOSPHATE ISOMERASE; JO 1 ANTIBODY; KERATIN ANTIBODY; RHEUMATOID FACTOR;

CELIAC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; EPITOPES; HUMANS; INFLAMMATION MEDIATORS;

EID: 73249137328     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2009.00856.x     Document Type: Review

References (194)

1. Lee AN, Beck CE, Hall M. Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review. Clin Lab Sci 2008 21 : 15 18.
2. Nishimura K, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007 146 : 797 808.
3. Vallbracht I, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004 63 : 1079 1084.
4. Pike RM, Sulkin SE, Coggeshall HC. Serological reactions in rheumatoid arthritis; factors affecting the agglutination of sensitized sheep erythrocytes in rheumatid-arthritis serum. J Immunol 1949 63 : 441 446.
5. Mewar D, Wilson AG. Autoantibodies in rheumatoid arthritis: a review. Biomed Pharmacother 2006 60 : 648 655.
6. Borque L, Olivan V, Iguaz F. Development and validation of an automated particle-enhanced nephelometric immunoassay method for the measurement of human plasma C1q. J Clin Lab Anal 1995 9 : 302 307.
7. Bas S, et al. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 2002 41 : 809 814.
8. Lutteri L, Malaise M, Chapelle JP. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 2007 386 : 76 81.
9. Vencovsky J, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003 62 : 427 430.
10. Renaudineau Y, et al. Rheumatoid factor on a daily basis. Autoimmunity 2005 38 : 11 16.
11. Theofilopoulos AN, et al. IgM rheumatoid factor and low molecular weight IgM. An association with vasculitis. Arthritis Rheum 1974 17 : 272 284.
12. De Rycke L, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005 64 : 299 302.
13. Wener MH, et al. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 2004 50 : 2305 2308.
14. Bombardieri M, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004 6 : R137 R141.
15. Pawlotsky JM, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995 122 : 169 173.
16. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009 76 : 818 824.
17. Lienesch D, et al. Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. J Rheumatol 2005 32 : 489 493.
18. Buskila D, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 1998 28 : 107 113.
19. Jonsson R, et al. Local IgA and IgM rheumatoid factor production in autoimmune MRL/lpr mice. Autoimmunity 1991 10 : 7 14.
20. Horai R, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000 191 : 313 320.
21. Taneja V, et al. CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J Immunol 2002 168 : 5867 5875.
22. Izui S, Eisenberg RA. Circulating anti-DNA-rheumatoid factor complexes in MRL/1 mice. Clin Immunol Immunopathol 1980 15 : 536 551.
23. Tighe H, et al. Human immunoglobulin (IgG) induced deletion of IgM rheumatoid factor B cells in transgenic mice. J Exp Med 1995 181 : 599 606.
24. Borretzen M, et al. Differences in mutational patterns between rheumatoid factors in health and disease are related to variable heavy chain family and germ-line gene usage. Eur J Immunol 1997 27 : 735 741.
25. Mantovani L, Wilder RL, Casali P. Human rheumatoid B-1a (CD5+ B) cells make somatically hypermutated high affinity IgM rheumatoid factors. J Immunol 1993 151 : 473 488.
26. Shlomchik MJ, et al. Variable region sequences of murine IgM anti-IgG monoclonal autoantibodies (rheumatoid factors). A structural explanation for the high frequency of IgM anti-IgG B cells. J Exp Med 1986 164 : 407 427.
27. Vossenaar ER, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003 48 : 2489 2500.
28. Masson-Bessiere C, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001 166 : 4177 4184.
29. Makrygiannakis D, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008 67 : 1488 1492.
30. Kuhn KA, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006 116 : 961 973.
31. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964 23 : 302 305.
32. Young BJ, et al. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979 2 : 97 99.
33. Sebbag M, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995 95 : 2672 2679.
34. Simon F, et al. Antibody avidity measurement and immune complex dissociation for serological diagnosis of vertically acquired HIV-1 infection. J Acquir Immune Defic Syndr 1993 6 : 201 207.
35. Schellekens GA, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998 101 : 273 281.
36. Girbal-Neuhauser E, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999 162 : 585 594.
37. Vincent C, et al. Subclass distribution of IgG antibodies to the rat oesophagus stratum corneum (so-called anti-keratin antibodies) in rheumatoid arthritis. Clin Exp Immunol 1990 81 : 83 89.
38. Manera C, et al. Clinical heterogeneity of rheumatoid arthritis and the antiperinuclear factor. J Rheumatol 1994 21 : 2021 2025.
39. Cordonnier C, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996 35 : 620 624.
40. Janssens X, et al. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. J Rheumatol 1988 15 : 1346 1350.
41. Vittecoq O, et al. Rheumatoid factors, anti-filaggrin antibodies and low in vitro interleukin-2 and interferon-gamma production are useful immunological markers for early diagnosis of community cases of rheumatoid arthritis. A preliminary study. Joint Bone Spine 2001 68 : 144 153.
42. Vossenaar ER, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004 6 : R142 R150.
43. Despres N, et al. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994 21 : 1027 1033.
44. Hayem G, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999 26 : 7 13.
45. Escalona M, et al. Anti-Sa sera from patients with rheumatoid arthritis contain at least 2 different subpopulations of anti-Sa antibodies. J Rheumatol 2002 29 : 2053 2060.
46. Xu S, et al. Anti-Sa antibody in Chinese rheumatoid arthritis. Chin Med J 1998 111 : 204 207.
47. Goldbach-Mansky R, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000 2 : 236 243. (Pubitemid 32223739)
48. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006 65 : 845 851.
49. dos Anjos LM, et al. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 2009 28 : 153 158.
50. van der Linden MP, et al. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009 60 : 2232 2241.
51. Rantapaa-Dahlqvist S, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003 48 : 2741 2749.
52. Nielen MM, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004 50 : 380 386.
53. Meyer O, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003 62 : 120 126.
54. Caspi D, et al. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. Arthritis Rheum 2006 55 : 53 56.
55. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987 30 : 1205 1213.
56. van der Helm-van Mil AH, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006 54 : 1117 1121.
57. Hill JA, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003 171 : 538 541.
58. Hill JA, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008 205 : 967 979.
59. Heliovaara M, et al. Smoking and risk of rheumatoid arthritis. J Rheumatol 1993 20 : 1830 1835.
60. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996 39 : 732 735.
61. Linn-Rasker SP, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006 65 : 366 371.
62. Klareskog L, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006 54 : 38 46.
63. Bardin T, et al. HLA antigens and seronegative rheumatoid arthritis. Ann Rheum Dis 1985 44 : 50 53.
64. de Man YA, et al. Women with rheumatoid arthritis negative for anti-CCP and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis 2009 doi :.
65. Petkova SB, et al. Human antibodies induce arthritis in mice deficient in the low-affinity inhibitory IgG receptor Fc gamma RIIB. J Exp Med 2006 203 : 275 280.
66. Boire G, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005 7 : R592 R603.
67. Bukhari M, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007 56 : 2929 2935.
68. Ingegnoli F, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol 2007 26 : 510 514.
69. Santiago M, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008 27 : 77 83.
70. Bogliolo L, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005 32 : 511 515.
71. Vander Cruyssen B, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005 64 : 1145 1149.
72. Alenius GM, Berglin E, Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006 65 : 398 400.
73. Inanc N, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007 26 : 17 23.
74. Korendowych E, et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology 2005 44 : 1056 1060.
75. Marchesoni A, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis: do classification criteria affect study results? J Rheumatol 2006 33 : 435. author reply 436-437.
76. Pasquetti P, Morozzi G, Galeazzi M. Very low prevalence of anti-CCP antibodies in rheumatoid factor-negative psoriatic polyarthritis. Rheumatology 2009 48 : 315 316.
77. Chan MT, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol 2008 35 : 77 83.
78. Zhao Y, et al. What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus? Joint Bone Spine 2009 76 : 501 507.
79. Qing YF, et al. The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus 2009 18 : 713 717.
80. Mediwake R, et al. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001 60 : 67 68.
81. Damian-Abrego GN, Cabiedes J, Cabral AR. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus 2008 17 : 300 304.
82. Fernandez A, et al. Lupus arthropathy: a case series of patients with rhupus. Clin Rheumatol 2006 25 : 164 167.
83. Simon JA, et al. Clinical and immunogenetic characterization of Mexican patients with 'rhupus'. Lupus 2002 11 : 287 292.
84. Panush RS, et al. 'Rhupus' syndrome. Arch Intern Med 1988 148 : 1633 1636.
85. Amezcua-Guerra LM, et al. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. Arthritis Res Ther 2006 8 : R144.
86. Kasapcopur O, et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004 63 : 1687 1689.
87. Avcin T, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002 61 : 608 611.
88. Kwok JS, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005 34 : 359 366.
89. Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Invest 2008 37 : 849 857.
90. Riccio A, et al. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J Biol Regul Homeost Agents 2008 22 : 57 61.
91. Mathsson L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008 58 : 36 45.
92. Mutlu N, et al. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis. J Rheumatol 2009 36 : 491 500.
93. Saulot V, et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 2002 46 : 1196 1201.
94. Kinloch A, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005 7 : R1421 R1429.
95. Kinloch A, et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum 2008 58 : 2287 2295.
96. Lundberg K, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008 58 : 3009 3019.
97. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999 341 : 2068 2074.
98. Bernstein RM, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J 1984 289 : 151 152.
99. Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000 12 : 475 481.
100. Mielnik P, et al. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity 2006 39 : 243 247.
101. Schmidt WA, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies - an evolving spectrum of disease manifestations. Clin Rheumatol 2000 19 : 371 377.
102. Miller FW, et al. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest 1990 85 : 468 475.
103. Yoshida S, et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983 26 : 604 611.
104. Stone KB, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007 56 : 3125 3131.
105. Hoffman IE, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004 63 : 1155 1158.
106. Hassfeld W, et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989 32 : 1515 1520.
107. Nell-Duxneuner V, et al. Autoantibody profiling in patients with very early rheumatoid arthritis - a follow-up study. Ann Rheum Dis 2009 doi :.
108. Hassfeld W, et al. Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum 1995 38 : 777 785.
109. Skriner K, et al. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J Clin Invest 1997 100 : 127 135.
110. Gabay C, Prieur AM, Meyer O. Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1993 52 : 785 789.
111. Tomoum HY, Mostafa GA, El-Shahat EM. Autoantibody to heterogeneous nuclear ribonucleoprotein-A2 (RA33) in juvenile idiopathic arthritis: clinical significance. Pediatr Int 2009 51 : 188 192.
112. Hayer S, et al. Aberrant expression of the autoantigen heterogeneous nuclear ribonucleoprotein-A2 (RA33) and spontaneous formation of rheumatoid arthritis-associated anti-RA33 autoantibodies in TNF-alpha transgenic mice. J Immunol 2005 175 : 8327 8336.
113. Hoffmann MH, et al. The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol 2007 179 : 7568 7576.
114. Monach PA, et al. Circulating C3 is necessary and sufficient for induction of autoantibody-mediated arthritis in a mouse model. Arthritis Rheum 2007 56 : 2968 2974.
115. Matsumoto I, et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999 286 : 1732 1735.
116. Schubert D, et al. Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice. J Immunol 2004 172 : 4503 4509.
117. Matsumoto I, et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol 2002 3 : 360 365.
118. Schaller M, Burton DR, Ditzel HJ. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2001 2 : 746 753.
119. Kassahn D, et al. Few human autoimmune sera detect GPI. Nat Immunol 2002 3 : 411 412. author reply 412-413.
120. Schubert D, et al. Autoantibodies to GPI and creatine kinase in RA. Nat Immunol 2002 3 : 411. author reply 412-413.
121. Herve CA, Wait R, Venables PJ. Glucose-6-phosphate isomerase is not a specific autoantigen in rheumatoid arthritis. Rheumatology 2003 42 : 986 988.
122. Matsumoto I, et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 2003 48 : 944 954.
123. Jouen F, et al. Diagnostic and prognostic values of anti glucose-6-phosphate isomerase antibodies in community-recruited patients with very early arthritis. Clin Exp Immunol 2004 137 : 606 611.
124. Kim JY, et al. Detection of antibodies against glucose 6-phosphate isomerase in synovial fluid of rheumatoid arthritis using surface plasmon resonance (BIAcore). Exp Mol Med 2003 35 : 310 316.
125. Cha HS, et al. Autoantibodies to glucose-6-phosphate isomerase are elevated in the synovial fluid of rheumatoid arthritis patients. Scand J Rheumatol 2004 33 : 179 184.
126. van Gaalen FA, et al. Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis. Arthritis Rheum 2004 50 : 395 399.
127. Schaller M, et al. Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Ann Rheum Dis 2005 64 : 743 749.
128. Goeb V, et al. Diagnostic and prognostic usefulness of antibodies to citrullinated peptides. Joint Bone Spine 2009 76 : 343 349.
129. Cook AD, et al. Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Res Ther 2004 6 : R477 R483.
130. Stuart JM, et al. Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic diseases as measured by 125I-radioimmunoassay. Arthritis Rheum 1983 26 : 832 840.
131. Andriopoulos NA, et al. Antibodies to human native and denatured collagens in synovial fluids of patients with rheumatoid arthritis. Clin Immunol Immunopathol 1976 6 : 209 212.
132. Cook AD, et al. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum 1999 42 : 2569 2576.
133. Cook AD, et al. IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 1997 24 : 2090 2096.
134. Raza K, et al. Anti-collagen type II antibodies in patients with very early synovitis. Ann Rheum Dis 2008 67 : 1354 1355.
135. Collier DH, et al. Anticollagen antibodies and immune response gene products in rheumatoid arthritis. Arthritis Rheum 1984 27 : 1201 1209.
136. Cho YG, et al. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007 7 : 65 70.
137. Nandakumar KS, et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. Eur J Immunol 2003 33 : 2269 2277.
138. Nandakumar KS, et al. Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res Ther 2004 6 : R544 R550.
139. Backlund J, et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 2002 99 : 9960 9965.
140. Meuwissen SG, et al. Ankylosing spondylitis and inflammatory bowel disease. I. Prevalence of inflammatory bowel disease in patients suffering from ankylosing spondylitis. Ann Rheum Dis 1978 37 : 30 32.
141. De Vos M, et al. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989 96 : 339 344.
142. Mielants H, et al. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988 27 (Suppl 95 105.
143. Leirisalo-Repo M. Enteropathic arthritis, Whipple's disease, juvenile spondyloarthropathy, and uveitis. Curr Opin Rheumatol 1994 6 : 385 390.
144. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976 55 : 401 412.
145. Palm O, et al. The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology 2001 40 : 1256 1261.
146. Atzeni F, et al. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J Gastroenterol 2009 15 : 2469 2471.
147. Aydin SZ, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology 2008 47 : 142 144.
148. Hoffman IE, et al. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003 62 : 455 459.
149. Torok HP, et al. Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion 2004 70 : 49 54.
150. Riente L, et al. Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J Rheumatol 2004 31 : 920 924.
151. Lakatos PL, et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis 2009 15 : 365 374.
152. Ewing C, et al. Antibody activity in ankylosing spondylitis sera to two sites on HLA B27.1 at the MHC groove region (within sequence 65-85), and to a Klebsiella pneumoniae nitrogenase reductase peptide (within sequence 181-199). J Exp Med 1990 171 : 1635 1647.
153. Ebringer A, et al. A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections. Clin Rheumatol 2007 26 : 289 297.
154. Frauendorf E, et al. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clin Exp Immunol 2003 134 : 351 359.
155. Tiwana H, et al. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatol Int 1997 17 : 11 16.
156. Sahly H, et al. Serum antibodies to Klebsiella capsular polysaccharides in ankylosing spondylitis. Arthritis Rheum 1994 37 : 754 759.
157. Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsiella - the evidence. Clin Rheumatol 2007 26 : 858 864.
158. Schwimmbeck PL, Yu DT, Oldstone MB. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med 1987 166 : 173 181.
159. Ebringer R, et al. Ankylosing spondylitis: klebsiella and HL-A B27. Rheumatol Rehabil 1977 16 : 190 196.
160. Trull AK, et al. IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol 1983 12 : 249 253.
161. Eastmond CJ, et al. Frequency of faecal Klebsiella aerogenes in patients with ankylosing spondylitis and controls with respect to individual features of the disease. Ann Rheum Dis 1980 39 : 118 123.
162. Maki-Ikola O, et al. IgM, IgG and IgA class enterobacterial antibodies in serum and synovial fluid in patients with ankylosing spondylitis and rheumatoid arthritis. Br J Rheumatol 1997 36 : 1051 1053.
163. Wilson C, et al. Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2003 30 : 972 978.
164. Fielder M, et al. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett 1995 369 : 243 248.
165. Sieper J, Kingsley GH, Marker-Hermann E. Aetiological agents and immune mechanisms in enterogenic reactive arthritis. Baillieres Clin Rheumatol 1996 10 : 105 121.
166. Koehler L, Zeidler H, Hudson AP. Aetiological agents: their molecular biology and phagocyte-host interaction. Baillieres Clin Rheumatol 1998 12 : 589 609.
167. Wollenhaupt J, Schnarr S, Kuipers JG. Bacterial antigens in reactive arthritis and spondarthritis. Rational use of laboratory testing in diagnosis and follow-up. Baillieres Clin Rheumatol 1998 12 : 627 647.
168. Granfors K, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989 320 : 216 221.
169. Wuorela M, Granfors K. Infectious agents as triggers of reactive arthritis. Am J Med Sci 1998 316 : 264 270.
170. Lapadula G, Covelli M, Numo R. Antibacterial antibody pattern in seronegative spondyloarthropathies (SNSA). Clin Exp Rheumatol 1988 6 : 385 390.
171. Toivanen A, et al. Association of persisting IgA response with yersinia triggered reactive arthritis: a study on 104 patients. Ann Rheum Dis 1987 46 : 898 901.
172. Granfors K, Toivanen A. IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis. Ann Rheum Dis 1986 45 : 561 565.
173. Granfors K., et al. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis Rheum 1998 41 : 855 862.
174. Taylor-Robinson D, et al. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet 1992 340 (8811 81 82.
175. Bas S, et al. Importance of species-specific antigens in the serodiagnosis of Chlamydia trachomatis reactive arthritis. Rheumatology 2002 41 : 1017 1720.
176. Granfors K, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990 335 : 685 688.
177. Gerard HC, et al. Molecular biology of infectious agents in chronic arthritis. Rheum Dis Clin North Am 2009 35 : 1 19.
178. Finch M, et al. Epidemic Reiter's syndrome following an outbreak of shigellosis. Eur J Epidemiol 1986 2 : 26 30.
179. Leirisalo-Repo M, Suoranta H. Ten-year follow-up study of patients with Yersinia arthritis. Arthritis Rheum 1988 31 : 533 537.
180. Herrlinger JD, Asmussen JU. Long term prognosis in yersinia arthritis: clinical and serological findings. Ann Rheum Dis 1992 51 : 1332 1334.
181. Simon DG, et al. Reiter's syndrome following epidemic shigellosis. J Rheumatol 1981 8 : 969 973.
182. Bowness P. HLA B27 in health and disease: a double-edged sword? Rheumatology 2002 41 : 857 868.
183. Lubrano E, et al. The arthritis of coeliac disease: prevalence and pattern in 200 adult patients. Br J Rheumatol 1996 35 : 1314 1318.
184. Briani C, Samaroo D, Alaedini A. Celiac disease: from gluten to autoimmunity. Autoimmun Rev 2008 7 : 644 650.
185. Lindfors K, Kaukinen K, Maki M. A role for anti-transglutaminase 2 autoantibodies in the pathogenesis of coeliac disease? Amino Acids 2009 36 : 685 691.
186. Lepore L, et al. Anti-alpha-gliadin antibodies are not predictive of celiac disease in juvenile chronic arthritis. Acta Paediatr 1993 82 : 569 573.
187. Kallikorm R, Uibo O, Uibo R. Coeliac disease in spondyloarthropathy: usefulness of serological screening. Clin Rheumatol 2000 19 : 118 122.
188. Lindqvist U, et al. IgA antibodies to gliadin and coeliac disease in psoriatic arthritis. Rheumatology 2002 41 : 31 37.
189. Togrol RE, et al. The significance of coeliac disease antibodies in patients with ankylosing spondylitis: a case-controlled study. J Int Med Res
190. Spadaro A, et al. (Anti-tissue transglutaminase antibodies in inflammatory and degenerative arthropathies). Reumatismo 2002 54 : 344 350.
191. Dockerty JL, Williamson L, Wordsworth BP. Endomysial antibodies in psoriatic arthritis patients. Rheumatology 2002 41 : 1195 1196.
192. Kia KF, et al. Prevalence of antigliadin antibodies in patients with psoriasis is not elevated compared with controls. Am J Clin Dermatol 2007 8 : 301 305.
193. Meyer O. Is the celiac disease model relevant to rheumatoid arthritis? Joint Bone Spine 2004 71 : 4 6. (Pubitemid 38183278)
194. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol 2005 117 : 207 213.